Evariste

🧪 Evariste x Orion 🧪 We are delighted to announce that Evariste has recently entered a collaboration with Orion Corporation! The agreement will involve the use of Evariste's Frobenius Discovery platform to design small molecule inhibitors for a target selected by Orion. We look forward to working with Orion's outstanding team to bring innovative medicines to patients, faster. 📰 Full press release: https://lnkd.in/ed65prnZ #Evariste #Orion #AIDrugDiscovery #Collaboration

We are attending today's AI For Health Summit in Paris, and are looking forward to hearing from distinguished speakers and networking with fellow biotechs. Be sure to reach out if you're around! #Evariste #TechBio #AIDrugDiscovery #SyntheticLethality #PKMYT1

We're excited to be featured among top industry players at next week's SAE Media Group AI in Drug Discovery USA conference in Boston! Our CSO Alfie Brennan will be taking part in a panel discussion titled: 'Strategising the Next Stage of AI Integration into Drug Discovery and the Pharmaceutical Industry', alongside world-class leaders and scientists from Novo Nordisk, Recursion, and Envisagenics. The panel is at 4:10 PM EDT on Monday 21st and is a must-see for all conference attendees! #Evariste #AIDrugDiscovery #SyntheticLethality #TechBio

Check out our recent poster presented at ELRIG Drug Discovery 2024! This case study with Evariste highlights how EditCo Bio's high-throughput cell engineering platform is transforming drug target identification and validation. Download now: https://hubs.la/Q02Tgg3Q0 #DrugDiscovery #CancerResearch #CellEngineering #GeneEditing #ELRIG2024 #AIinBiotech

Looking forward to presenting our collaborative work with EditCo Bio at #ELRIG this week!

Evariste will be attending the SwedenBIO NLS Days conference in Malmö today and tomorrow. Ping us on the partnering platform or LinkedIn to catch up! #Evariste #SyntheticLethality #TechBio #AIDrugDiscovery

We're excited to have been selected to pitch at the Startup Spotlight at ChinaBio Partnering Forum, held in Shanghai on September 10-11! Evariste will be pitching alongside several other young startups at the forum developing new therapeutic solutions, technologies and digital platforms, on Wednesday 11th September 9:00-10:30AM. We will also be taking partnering meetings with prospective pharma/biotech partners and investors throughout the conference, so be sure to reach out on PartneringOne or LinkedIn to set up a meeting! #Evariste #AIDrugDiscovery #SyntheticLethality #TechBio #ChinaBio2024

Our very own Principal Scientist, Daniel Miller is the featured expert in EditCo Bio’s upcoming webinar: AI-driven identification and validation of novel synthetic lethal gene pairs.  The webinar will discuss how Evariste leverages AI to accelerate drug discovery, utilizing EditCo's CRISPR Express Cell Pools and Arctoris' Ulysses® to drive rapid target validation. Topics covered include: 🔬 Synthetic lethality (SL) as a promising, untapped oncology strategy, with currently limited actionable targets. 🔍 How Evariste uses Frobenius Target to identify novel SL gene pairs and validates them using high-throughput CRISPR editing and robotic cell biology assays. 💡 Case study on a novel SL pair involving the oncology target FAK, showcasing the platform’s ability to identify a pipeline of clinically actionable targets. Danny will be joined by industry leaders Travis Hardcastle from EditCo and Kinga Bercsenyi from Arctoris. Their expertise, combined with Danny's insights, will make this a must-attend webinar! 🗓️ Date: 18th July, 12:00 EST 📝 Register now: https://lnkd.in/ePREsEJX #Evariste #EditCo #Arctoris #AIDrugDiscovery #SyntheticLethality #TechBio #CRISPR

🚀 Evariste x NVIDIA Inception 🚀 We're thrilled to announce that Evariste has joined NVIDIA Inception, a program that supports young companies transforming industries with their technological advancements. We firmly believe that the support provided by NVIDIA will enhance the capabilities of Frobenius, our AI-enabled drug discovery platform, which excels at working with small and noisy biological datasets to identify novel blockbuster synthetic lethal targets and discover best-in-class small molecule therapeutics. As part of Inception, we will have access to NVIDIA's cutting-edge technology, expertise, and a network of like-minded teams. We are particularly excited about the support for our future exploratory research projects, which involve computationally intensive tasks. Technical assistance and access to cloud compute credits from NVIDIA will be invaluable for these projects. This development comes at an exciting time for Evariste, with promising preclinical data coming in for our lead #PKMYT1 program, as well as rapidly progressing early programs, which all serves as crucial proof-of-concept for Frobenius. If you would like to join us on our journey to transform drug discovery as a partner or an investor, we would love to hear from you! Stay tuned for more updates. 🕑 #Evariste #NVIDIAInception #AIDrugDiscovery #SyntheticLethality #TechBio

Outstanding talk by Alfie Brennan from Evariste about their #AI-enable platform #FrobeniusDiscovery for precision Oncology. Full integration with #Torx from Cresset and Collaborative Drug Discovery - CDD Vault . #CressetUGM2024 #Elixir #drugdiscovery #AIDrugDiscovery #SBDD